Characteristics of the cohort and index thrombotic event per group
| Variable . | Non-LR (N = 56) . | LRneonates (N = 95) . | LRnon-neonates (N = 188) . | P . |
|---|---|---|---|---|
| Age at DVT diagnosis, median (25th, 75th percentile) | 14.5 y (12.2-16.4) | 8 d (4-16) | 198 d (67-931) | <.001*† |
| Follow-up time, median (25th, 75th percentile), y | 2.0 (1.1-4.5) | 4.3 (2.5-9.6) | 3.5 (2.1-9.3) | <.001* |
| Sex ratio (male/female) | 0.7 | 1.4 | 1.4 | .05‡ |
| Underlying conditions at the time of DVT diagnosis, n (%) | ||||
| None | 34 (61%) | 0 (0%) | 0 (0%) | — |
| CHD | 0 (0%) | 60 (63%) | 68 (36%) | |
| Cancer | 2 (3%) | 1 (1%) | 6 (3%) | |
| Autoimmune and inflammatory diseases | 8 (14%) | 1 (1%) | 3 (2%) | |
| Infectious disease | 7 (13%) | 2 (2%) | 29 (15.5%) | |
| Prematurity | 0 (0%) | 8 (8%) | 20 (11%) | |
| Other | 5 (9%) | 9 (10%) | 55 (29%) | |
| CDH | 0 (0%) | 14 (15%) | 1 (0.5%) | |
| HUS | 0 (0%) | 0 (0%) | 6 (3%) | |
| Thrombophilia,§n (%) | ||||
| Major | 18 (34%) | 3 (4%) | 9 (7%) | .001|| |
| Minor | 17 (32%) | 10 (15%) | 9 (7%) | |
| None | 18 (34%) | 55 (81%) | 113 (86%) | |
| Symptoms of acute DVT, n (%) | 51 (91%) | 79 (83%) | 149 (79%) | .11|| |
| DVT location, n (%) | ||||
| Ilio-femoral | 42 (75%) | 95 (100%) | 184 (98%) | <.001|| |
| Femoro-popliteal | 14 (25%) | 0 (0%) | 4 (2%) | |
| Numbers of segments affected, median (25th, 75th percentile) | 3.5 (2-5) | 2 (2-3) | 2 (1-3) | <.001* |
| Occlusive DVT (at least 1 segment), n (%)¶ | 48 (87%) | 80 (88%) | 134 (74%) | .01|| |
| Laterality, n (%) | ||||
| Right | 28 (50%) | 60 (63%) | 107 (57%) | .61‡ |
| Left | 24 (43%) | 29 (31%) | 68 (36%) | |
| Bilateral | 4 (7%) | 6 (6%) | 13 (7%) | |
| Therapeutic modality for DVT, n (%) | ||||
| Anticoagulant treatment | 36 (64%) | 92 (97%) | 172 (91.5%) | <.001|| |
| Thrombolysis | 18 (32%) | 0 (0%) | 1 (0.5%) | |
| No treatment or prophylaxis only | 2 (4%) | 3 (3%) | 15 (8%) | |
| Delay to full dose therapy, median (25th, 75th percentile), d | 0 (0-2) | 0 (0-1) | 0 (0-1) | .11* |
| Length of treatment, median (25th, 75th percentile), d | 365 (181-381) | 91 (83-128) | 92 (87-109) | <.001* |
| Variable . | Non-LR (N = 56) . | LRneonates (N = 95) . | LRnon-neonates (N = 188) . | P . |
|---|---|---|---|---|
| Age at DVT diagnosis, median (25th, 75th percentile) | 14.5 y (12.2-16.4) | 8 d (4-16) | 198 d (67-931) | <.001*† |
| Follow-up time, median (25th, 75th percentile), y | 2.0 (1.1-4.5) | 4.3 (2.5-9.6) | 3.5 (2.1-9.3) | <.001* |
| Sex ratio (male/female) | 0.7 | 1.4 | 1.4 | .05‡ |
| Underlying conditions at the time of DVT diagnosis, n (%) | ||||
| None | 34 (61%) | 0 (0%) | 0 (0%) | — |
| CHD | 0 (0%) | 60 (63%) | 68 (36%) | |
| Cancer | 2 (3%) | 1 (1%) | 6 (3%) | |
| Autoimmune and inflammatory diseases | 8 (14%) | 1 (1%) | 3 (2%) | |
| Infectious disease | 7 (13%) | 2 (2%) | 29 (15.5%) | |
| Prematurity | 0 (0%) | 8 (8%) | 20 (11%) | |
| Other | 5 (9%) | 9 (10%) | 55 (29%) | |
| CDH | 0 (0%) | 14 (15%) | 1 (0.5%) | |
| HUS | 0 (0%) | 0 (0%) | 6 (3%) | |
| Thrombophilia,§n (%) | ||||
| Major | 18 (34%) | 3 (4%) | 9 (7%) | .001|| |
| Minor | 17 (32%) | 10 (15%) | 9 (7%) | |
| None | 18 (34%) | 55 (81%) | 113 (86%) | |
| Symptoms of acute DVT, n (%) | 51 (91%) | 79 (83%) | 149 (79%) | .11|| |
| DVT location, n (%) | ||||
| Ilio-femoral | 42 (75%) | 95 (100%) | 184 (98%) | <.001|| |
| Femoro-popliteal | 14 (25%) | 0 (0%) | 4 (2%) | |
| Numbers of segments affected, median (25th, 75th percentile) | 3.5 (2-5) | 2 (2-3) | 2 (1-3) | <.001* |
| Occlusive DVT (at least 1 segment), n (%)¶ | 48 (87%) | 80 (88%) | 134 (74%) | .01|| |
| Laterality, n (%) | ||||
| Right | 28 (50%) | 60 (63%) | 107 (57%) | .61‡ |
| Left | 24 (43%) | 29 (31%) | 68 (36%) | |
| Bilateral | 4 (7%) | 6 (6%) | 13 (7%) | |
| Therapeutic modality for DVT, n (%) | ||||
| Anticoagulant treatment | 36 (64%) | 92 (97%) | 172 (91.5%) | <.001|| |
| Thrombolysis | 18 (32%) | 0 (0%) | 1 (0.5%) | |
| No treatment or prophylaxis only | 2 (4%) | 3 (3%) | 15 (8%) | |
| Delay to full dose therapy, median (25th, 75th percentile), d | 0 (0-2) | 0 (0-1) | 0 (0-1) | .11* |
| Length of treatment, median (25th, 75th percentile), d | 365 (181-381) | 91 (83-128) | 92 (87-109) | <.001* |
CDH, congenital diaphragmatic hernia; CHD, congenital heart disease; HUS, hemolytic uremic syndrome; IBD, inflammatory bowel disease.
Kruskal-Wallis test.
Same P value for comparison between LR vs Non-LR groups.
χ2 test.
Minor thrombophilia: increased FVIII or plasma lipoprotein(a), heterozygous FVL, or PTG mutation. Major thrombophilia: PC, PS, or AT deficiency, positive LAC or ACLAs, FVL or PTG homozygous mutation, or double-heterozygous FVL/PTG mutation.
Fisher’s exact test.
Information available for Non-LR (n = 55), LRneonates (n = 91), and LRnon-neonates (n = 181).